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ights reserved.1. Introduction
The plasma membrane represents the barrier of life, the structure
that separates living cells from their surroundings. For many years,
lipids were not considered to be involved in such important events as
cell signaling or local hormonal regulation. Indeed, it was many years
after linoleic acid (LA)was demonstrated to be an essential dietary con-
stituent that the importance of this ﬁndingwas recognized by the scien-
tiﬁc community [1]. A major milestone was reached in 1979 with the
discovery of the ﬁrst biologically active phospholipid, the platelet-
activating factor [2]. Since then, lipids have been found to fulﬁll some
Table 1
Changes in the phase transition temperature of phospholipids upon incubation with
different hydroxylated and non-hydroxylated fatty acids.
Lipid under study Fatty acid Effect Technique Reference
DPPC
Lβ-to-Lα 40.8 °C
30 mol% SA 41.3 °C aDSC, FL [29]
30 mol% OA 37.5 °C
30 mol% EPA 36.3 °C
30 mol% DHA 36.2 °C
DEPE
Lα-to-HII 65.5 °C
5 mol% SA 66 °C XRD [34]
5 mol% OA 53 °C XRD, 31P
NMR
[34,35]
5 mol% EA 59 °C XRD [34,36]
5 mol% 2OHOA 55 °C DSC, XRD
POPE
Lα-to-HII 70 °C
2.5 mol% OA 51 °C XRD [34]
DMPC
Lβ-to-Lα 23.4 °C
5 mol% SA 24.3 °C DSC [38]
5 mol% OA 22.6 °C
5 mol% (+)-
Ricinoleic acid
22.0 °C
5 mol% R/S-2-OH
octadecanoic
acid
24.3 °C
5 mol% R/S-2-OH
hexadecanoic
acid
24.5 °C
5 mol% R/S-3-OH
hexadecanoic
acid
24.3 °C
a DSC, differential scanning calorimetry; FL, ﬂuorescence spectroscopy; XRD, X-ray dif-
fraction; and NMR, nuclear magnetic resonance.
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energy or as simple building blocks of membranes. Indeed, it is now
recognized that membrane lipids inﬂuence the trafﬁcking of cellular
constituents, as well as the activity of membrane proteins and signals.
Cell membranes are composed of thousands of different lipid mole-
cules that interact dynamically to form the transient or stable structures
thatmay be used bymany proteins as platforms for their activity, and to
enhance their interactionswith other proteins. Lipids are a large and di-
verse group of naturally occurring organic compounds that share com-
mon physical properties, such as their solubility in non-polar organic
solvents and general insolubility in water. In terms of membrane com-
position, lipids can be classiﬁed into different groups: glycerolipids,
sphingolipids and terpene-derived lipids (e.g., sterols). Fatty acids may
contribute to complex lipids, although they can be also found as free en-
tities in the membrane. In addition, fatty acids are ubiquitously present
in animal fats, vegetable oils or waxes.
Like lipids in general, fatty acids are now no longer considered as
a mere energy source but rather, they have generated great interest
due to their involvement in human health. In recent years, dietary
recommendations have been made to decrease the intake of saturat-
ed and trans-fatty acids due to their negative cardiovascular effects,
while mono- and polyunsaturated fatty acids are recommended for
their cardio-protective beneﬁts [3]. For instance, oleic acid (OA)
has been associated with a reduction in blood pressure and a lower
incidence of hypertension [4]. Docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) have also been associatedwith the preven-
tion of cardiovascular diseases and cancer [5], while the omega−6
polyunsaturated fatty acid (PUFA), gamma linolenic acid (γ-LNA), is
known to possess anti-inﬂammatory properties [6]. In addition, altered
levels of free fatty acids (FFAs) have been associated with pathological
states, as in diseases like obesity, hypertension, diabetes mellitus, coro-
nary heart disease, alcoholism, schizophrenia, Alzheimer's disease (AD),
atherosclerosis and cancer [7]. A study carried out on autistic children
between 5 and 8 years-of-age showed that they had increased plasma
levels of most saturated fatty acids, except for propionic acid, while
the concentration of PUFAs was decreased [8]. Other studies showed
that both adult and elderly mice reproduced by assisted reproductive
technologies, such as in vitro fertilization and intra-cytoplasmic sperm
injection, contained lower monounsaturated fatty acid (MUFA) and
higher PUFA levels. However, the levels of saturated fatty acids were
altered in adult but not in old mice. All these changes might reﬂect
potential effects on the health of animals [9].
In this review, themain effects of natural and synthetic fatty acids
as modulators of membrane structure, microdomain organization and
cellular signaling are described, focusing on the human health beneﬁts
and the new therapeutic approaches that have been developed.
2. Effects of natural and synthetic fatty acids onmembrane structure
Fatty acids may exert structural effects on membranes, either as
free entities (i.e. FFA) or as part of other molecules such as phospho-
lipids and triacylglycerides. The interaction of FFA with membranes
and their incorporation in more complex molecules occurs within
minutes. Thus, it is observed that externally added OA in phosphati-
dylcholine (PC) giant unilamellar vesicle solutions induces vesicle
swelling after 3 min [10], indicating that the insertion of the FFA
within the membrane structure takes place within that period of time.
Another study also described a destabilization of giant unilamellar ves-
icles composed of palmitoyl-oleoyl-phosphatidylcholine:phosphatidyl-
ethanolamine:sphingomyelin:cholesterol (POPC:PE:SM:Cho; 1:1:1:1;
mol ratio) after 3-min incubation with OA, arachidonic acid (ARA) and
DHA [11]. Interestingly, the same effect was observed when using
their 2-hydroxylated, synthetic analogs 2-hydroxyoleic (2OHOA),
2-hydroxyarachidonic (2OHARA) and 2-hydroxydocosahexaenoic
(2OHDHA) acid [11]. Concerning the esteriﬁcation of natural FFA, it
is known that the omega−3 eicosapentanoic acid may be detected aspart of phospholipids and triacylglycerols in rat liver, brain and heart
within 5 min after intravenous infusion [12]. Moreover, the synthetic
FFA, 2OHOA, has also been detected in PC, PE, phosphatidylinositol
and phosphatidylserine from U118 human, glioma cells, 2–24 h after
incubation with this lipid [13]. All in all, the rapid insertion of FFA into
membranes and their incorporation in more complex molecules enable
these acyl chains to induce changes in the structure of lipid bilayers.
Since the seventies, the effects of fatty acids on model membrane
structure have been studied using a variety of techniques, including
differential scanning calorimetry (DSC) [14–17], ﬂuorescence spec-
troscopy [18–20], electron spin resonance [21,22], light scattering
[23], electrophoresis [24], nuclearmagnetic resonance [25], scanning
densitometry [26] and differential thermal analysis [17]. Together,
these studies have shown that long-chain saturated fatty acids increase
the gel-to-ﬂuid phase (Lβ-to-Lα) transition temperature (also known as
melting temperature, Tm) of phospholipid bilayers, whereas short-
chain or cis-unsaturated fatty acids decrease the Tm. Thus, the length
and degree of unsaturation of natural FFAs affect their impact on mem-
brane lipid structure [27]. The perturbations induced by these fatty
acids onmembrane lipid structure involve changes in membrane ﬂuid-
ity, phase behavior, permeability, membrane fusion, lateral pressure
and ﬂip-ﬂopdynamics. For instance, it has been proposed that FFAs per-
turb the lipid bilayer, and that they disturb the protein–lipid interac-
tions in human erythrocyte membranes [28].
The addition of unsaturated FFAs to liposomes formed by DPPC has
also been studied; DHA and EPA particularly producing a broadening
and a shift of the Tm values of DPPC to lower temperatures (Table 1).
The phase transition temperature and 1,6-diphenyl-1,3,5-hexatriene
(DPH) ﬂuorescence anisotropy values at 37 °C decrease progressively
with increasing amounts of unsaturated fatty acids, while Triton X-
100 solubilization is facilitated by the presence of unsaturated fatty
acids. These data suggest that the tightly packed DPPC bilayer becomes
more disordered and ﬂuid when it contains DHA and EPA [29].
Membrane ﬂuidity plays an important role in cellular functions
since the activity of membrane proteins is modulated by the sur-
rounding lipid environment. In this case, lipids may inﬂuence the op-
timal conformation for the catalytic activity of proteins by changing
the membrane's biophysical properties [30]. For instance, it was pro-
posed that FFAs affect non-speciﬁc interactions with the lipid bilayer,
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ﬁnally leading to changes in the activity of the human erythrocyte
membrane sodium pump [31,32]. It has also been shown that human
neutral sphingomyelinase activity in red blood cells is modiﬁed by the
surface tension of the membrane, which is in turn modulated by the
lipid composition of the bilayer [33].
The effect of FFAs on the phase behavior of fully-hydrated lipid mix-
tures has been measured by a variety of methods (see Table 1). X-ray
diffraction experiments show that OA, LA and alpha linolenic acid (α-
LNA) signiﬁcantly decrease the Lα-to-HII phase transition temperature
(TH) of ethanolamine-containing phospholipids 1,2-dielaidoyl-sn-
glycero-3-phosphoethanolamine (DEPE) and 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine (POPE) [34,35]. Unlike OA, its trans-
double bonded analog elaidic acid (EA) and the saturated stearic acid
(SA) induce smaller changes in the structural properties of DEPE. Exper-
iments donewith the synthetic cis-monounsaturated fatty acid, 2OHOA,
show that this FFA reduces the temperature atwhichDEPE forms theHII
phase and that it destabilizes the lamellar phase [36].Molecular dynam-
ics simulations conﬁrm the effect of 2OHOA on the structural parame-
ters of membranes composed of DEPE [37]. Interestingly, unsaturated
fatty acids have a greater effect on the TH than on Tm. For instance,
30 mol% OA induces a 3 °C reduction in the Tm of DPPC, while
2.5 mol% induces an ~20 °C reduction in the TH (Table 1). This suggests
that surface packing and lateral pressure are more affected by MUFAs
than ﬂuidity.
DSC of 1,2-dimirystoyl-sn-glycero-3-phosphocholine (DMPC)
vesicles was performed in the presence of 5 mol% saturated, mono-
unsaturated and hydroxylated FFAs. SA slightly elevated the Tm by
about 1 °C, whereas OA decreased it by 1 °C compared to pure DMPC
vesicles. The addition of a hydroxyl group to the carbon 12 of OA
(ricinoleic acid) further stabilized the ﬂuid phase by decreasing the
Tm value. When using the 12-hydroxylated SA derivative, the Tm
value was not modiﬁed compared to the pure DMPC, although the sta-
bilization of the\OH group on the Lα phase was conﬁrmed by a reduc-
tion in the enthalpy of the phase transition. A different pattern is
observed in the presence of hydroxylated fatty acids containing the hy-
droxyl group near the hydrophilic carboxyl end. Here, 2-hydroxystearic
acid, 2-hydroxypalmitic acid and 3-hydroxypalmitic acid increased the
Tm value in a similar way as SA [38] (Table 1).
The effect of FFAs on membrane permeability has been associated
with membrane disorder [39]. It is known that at the gel-to-ﬂuid
phase transition of DMPC, when the largest number of defects in the
lipid matrix appears, membrane permeability reaches its maximum
[40]. Unsaturated FFA prevents iodide and dithionite ion perme-
abilization without modifying the thermodynamic properties of
DMPC bilayers, whereas saturated FFAs show little effect. The postu-
lated mechanism of action suggests that unsaturated FFA affects
defected areas within the membrane and prevents ions from crossing
the lipid membrane [41]. It has also been demonstrated that DHA
more effectively increases permeability than its metabolic precursor,
LA or OA [42]. DHA can increase the permeability of phospholipid vesi-
cles and T27A tumor cells, as monitored by vesicle swelling in isomolar
erythritol and leakage of sequestered carboxylﬂuorescein. DHA is incor-
porated into lipid vesicles either as a FFA or as part of a phospholipid in
1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine [43].
Due to their inverted conical shape, FFAs have been postulated to
participate in fusion processes [44]. The idea that amphipathic mole-
culesmight act as intermediates inmembrane fusionwasﬁrst proposed
some years ago [45]. For instance, FFAs containing 10 to 22 carbon
atoms were shown to induce the fusion of erythrocytes [46] or model
membranes [16]. In model systems, an increase in the size of vesicles
composed of saturated PC was observed above a threshold concentra-
tion of saturated FFA at temperatures slightly below the lipid phase
transition temperature [47]. When isolated chromafﬁn granules (the
secretory vesicles of the adrenal medulla) are aggregated by synexin
(a calcium-binding protein present in chromafﬁn cells and othersecretory tissues) and then exposed to cis-unsaturated fatty acids at
37 °C, they fuse together to form large vesicles, as determined by
phase and electron microscopy, and by turbidity measurements. ARA
and OA are the most effective fusogens, whereas saturated and trans-
unsaturated fatty acids are inactive [48]. FFAs have also been implicated
in membrane fusion mediated by proteins of the SNARE family since
they can act on syntaxin, a plasma membrane protein directly involved
in vesicle fusion [49–51].
Regarding the effect of fatty acids as part of phospholipids, DHA is
an example of a fatty acid that affects biophysical parameters of the
membrane bilayer, such as lipid packing, the membrane transition
temperature, curvature, inter-leaﬂet lipid ﬂip-ﬂop rate, lipid phase
separations and permeability [52,53]. For instance, DHA can provoke
the phase separation of bilayers composed of 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) and 1-oleoyl-2-docosahexanoyl-
sn-glycero-3-phosphocholine [43,54]. Although DHA is not likely to
greatly change the spontaneous curvature of the membrane, the
high ﬂexibility of this molecule [53,55] causes a marked reduction
in the bending and saddle splay moduli [56].
3. Effects of natural and synthetic fatty acids on membrane
microdomain organization
Biological membranes are not homogeneous lipid mixtures but
rather, they are composed of dynamic lipid and protein clusters re-
ferred to as microdomains that differ in composition from their
ﬂanking regions [57]. It is likely that lipid microdomains form within
cell membranes, at least in part, as a consequence of the distinct af-
ﬁnities between lipids [58], and that these localized lipid patches
have unique compositions that establish environments that favor
the activity of speciﬁc proteins. Recently, there has been great inter-
est in one particular type of lipid domain, the lipid raft. Rafts are
sphingolipid- and Cho-enriched liquid-ordered (Lo) domains ﬂoat-
ing in “a sea” of liquid-disordered (Ld) phospholipids [59]. Their bi-
ological interest stems from the close association of lipid rafts with
essential cell signaling proteins, including lipid-linked proteins,
such as the src kinase family in the inner leaﬂet and GPI-anchored
proteins in the outer plasma membrane leaﬂet [60].
While there are compelling reasons to believe that lipid domains
exist, and they have been clearly demonstrated in model lipid mono-
layers and bilayers, their precise nature, composition, size and life-
time/dynamics in biological membranes still remains controversial
[61]. The problem resides in the process used to isolate lipid rafts.
Traditional methods to isolate rafts from cultured cells and tissue
samples have exploited the biochemical properties of these micro-
domains: their relative resistance to solubilization by non-ionic de-
tergents at 4 °C; and their light buoyant density attributable to
their high Cho and sphingolipid content. Thus, raft microdomains are
commonly isolated by density gradient separation in the presence of
0.5–1% Triton X-100. This and other detergent-based methods have
been discussed extensively, and new methods to isolate rafts from cul-
tured cells without the use of detergents have also been proposed [62].
Techniques that allow researchers to track and manipulate single mol-
ecules or small groups of molecules in the cell membranes of living
cells have become widely available. These methods include single ﬂuo-
rescentmolecule video imaging usingﬂuorescent probes, single particle
tracking using colloidal-gold probes, and optical trapping, which allows
researchers to move gold particle-conjugated molecules in living cell
membranes [63–65]. These methods that enable researchers to see
and grab singlemolecules in living cells will greatly advance our under-
standing about the cell membrane functions. Although such studies
have only been initiated recently, they have already started to yield
new signiﬁcant insights that could not have been obtained without ob-
servations at the level of each individual molecule [66]. Although the
idea of membrane domains seems relatively novel, lipid domains in bi-
ological membranes and their implication in cell function were ﬁrst
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partitioning of FFAs into membranes could selectively perturb lipid do-
mains in membranes, and that such perturbation could disturb the be-
havior of proteins embedded in such lipid domains [19,68,69].
Studies using free 2OHOA in model membranes showed that the
packing of ordered domains is enhanced while the global order of the
membrane decreases [13]. In addition, 15 mol% of OA, ARA, DHA and
their 2-hydroxylated analogs 2OHOA, 2OHARA and 2OHDHA were
recently shown to increase cell membrane ﬂuidity when incorporated
into lipid bilayers (palmitoyl-oleoyl PC:PE:SM:Cho; 1:1:1:1; mol
ratio), reducing the Lo/Ld ratio from ca. 50 to ca. 40%. In addition, the
insertion of both natural and synthetic FFAs into model membranes
induces a transformation of the lipid structures into newmicrodomains
that differ in size and composition from their initial situation (Fig. 1).
This reorganization of lipid microdomains is thought to modulate the
localization of signaling proteins, thereby controlling their intracellular
cascades [11].
The mouse ﬁbroblast plasma membrane is an excellent model sys-
tem to study how fatty acids inﬂuence the membrane, since it contains
no PUFAs when cultured in serum-free, chemically deﬁned medium
[70]. The fatty acyl composition of phospholipids frommouse ﬁbroblast
cells is dramatically altered by supplementing the culture mediumwith
LA and LNA. It has been shown that the addition of these two fatty acids
decreases the molecular order of the membrane and changes the orga-
nization of different domains by transbilayer sterol redistribution
[70,71]. Thus, in plasma membrane from mouse ﬁbroblasts without FA
in the cell medium, the cytosolic leaﬂet is enriched in sterol, while the
presence of PUFA the transbilayer sterol gradient is reversed. In smooth
muscle cells, Cho efﬂux increased on exposure to EPA andDHA,whereas
OA, LA or ARA has no effect on this process [72].
Alzheimer's disease is a neurodegenerative disorder characterized
by the accumulation of amyloid β (Aβ) in perivascular deposits and se-
nile plaqueswithin the brain. The intake of the DHAhas been associated
with decreased amyloid deposition and reduced risk of AD in several but
not all, epidemiological studies [8]. However the exact molecular mech-
anism underlying this effect of DHA remains unknown. DHA is a major
component of ﬁsh oils and it is required for the adequate development
of the human central nervous system, aswell as for the continuedmain-
tenance of brain cell functions. It has been shown that DHA-containing
phospholipids affect the organization of plasma membranes, inducing
changes in raft and non-raft domains [73]. Isothermal titration calorim-
etry and molecular dynamics simulations have shown that monomeric
Aβ42 binds more tightly to Ld regions than to Lo ones to model mem-
branes [74]. Meanwhile, Aβ peptide dimers accumulate in Lo, lipid raft
domains in mice [75]. Together, it appears that the organization of
membrane microdomains is implicated in the binding of Aβ to the
membrane, and that DHA can control the accumulation of these de-
posits by modulating the distribution of Lo and Ld domains.
Although it has not been demonstrated, the mechanism of action of
DHA could be similar to other fatty acid derivatives such as the syntheticFig. 1.Model of lipid domain reorganization induced by natural and 2-hydroxylated
FAderivatives upon insertion into artiﬁcialmembranes. The Lo/Ld domain ratio is reduced
from ca. 50% to ca. 40% of the total membrane surface upon insertion of fatty acid and
2-hydroxylated fatty acid derivatives into a lipid membrane. The size of the Lo and Ld
domains decreases and the lipid composition is modiﬁed.
Taken from [11], with permission.alkylphospholipids edelfosine and miltefosine. These molecules modify
the plasma membrane lipid composition, namely Cho and SM content,
inducing raft coalescence and provoking apoptosis in several cancer
cells [76]. Fluorescence lifetime imaging microscopy measurements in
Jurkat cells show that edelfosine andmiltefosine do not signiﬁcantly af-
fect the membrane biophysical properties of both model and cell mem-
branes. However, a slight disordering of themembrane was detected in
model membrane systems [77].
4. Effects of natural and synthetic fatty acids on cell signaling
and pathophysiology
The effects of FFAs on membrane structure are of particular interest
as they inﬂuence membrane protein function and signal propagation.
FFAs have been shown to act both as modulators and messengers,
particularly of signals triggered at the level of cell membranes. The
multiple effects of FFAs appear to involve the positive or negative regu-
lation of awide range of signaling cascades (e.g., inositol phosphateme-
tabolism, inﬂammation and calcium-dependent signaling).
The relationship between membrane fatty acid composition and
inositol phosphate metabolism has been studied in human colon
tumor cells cultured in media with different concentrations of satu-
rated and unsaturated fatty acids. This study showed that PUFAs in-
crease the response of the inositol phosphate cycle to deoxycholic
acid stimulation [78]. In addition, enrichment in omega−3 α-LNA
increases the basal turnover of inositol phosphate. All in all, alter-
ations in membrane fatty acids have a profound effect on the inositol
phosphate cycle. Fatty acids are also closely related to inﬂammation
since eicosanoids, mediators and regulators of inﬂammation, are
generated from 20-carbon PUFAs. Indeed, the mechanism by which
non-steroidal anti-inﬂammatory drugs induce apoptosis in human
colorectal cancer cells seems to be related to the levels of fatty
acids. These drugs inhibit the activity of cyclooxygenases, which in-
creases the cellular pool of ARA. At the same time, ARA stimulates
neutral sphingomyelinase activity [79], which catalyzes the hydroly-
sis of SM to generate ceramide, a pro-apoptotic second messenger
[80]. While ARA is considered as a pro-inﬂammatory lipid, EPA and
DHA have been studied as anti-inﬂammatory molecules due to
their capacity to reduce the production of pro-inﬂammatory cyto-
kines via the NF-κB signaling pathway [81]. Moreover, EPA is itself
a substrate for cyclooxygenase and lipoxygenase, giving rise to medi-
ators that often have opposite biological effects to those of ARA.
Concerning calcium-dependent signaling pathways, it is well known
that calcium is a vital intracellular second messenger that governs a
wide array of cellular processes. There is considerable evidence that
the accumulation of membrane-derived FFAs is important in the
pathogenic events caused by myocardial ischemia [82]. Low concen-
trations of long-chain unsaturated and saturated fatty acids induce
multifold increases in voltage-dependent calcium currents in cardiac
myocytes, which causes irreversible cardiac damage. By contrast,
neither short-chain fatty acids nor fatty acid esters have any effect
on voltage dependent calcium currents, indicating that activation
of calcium channels depends on chain length and requires a free car-
boxyl group. Moreover, inhibition of protein kinase C (PKC), PKA, G
proteins, eicosanoid production, or non-enzymatic oxidation does
not block the fatty acid-induced increases in intracellular calcium.
Thus, long-chain fatty acids appear to be activators of calcium chan-
nels by possibly acting at lipid speciﬁc sites near the channel or
directly on the protein channel itself [82]. In human keratinocytes,
triglycerides and saturated fatty acids do not affect the intracellular
calcium concentration, whereas unsaturated fatty acids increase in-
tracellular calcium, altering the calcium dynamics in epidermal
keratinocytes and inducing abnormal follicular keratinization [83].
LA has also been related to calcium signaling since it binds to
mouse CD36-positive gustatory cells, it induces Src-PTK phosphory-
lation, it triggers calcium signaling, and it evokes the release of 5-
Fig. 2. Mechanism of action of 2OHOA. 2OHOA induces the translocation of PKC to the
membrane and its subsequent activation. This activation leads to p21 overexpression,
which is associated with the hypophosphorylation of pRB, and the ensuing inhibition of
E2F-1 and silencing of DHFR. Conversely, Ras is translocated to the cytoplasm in the pres-
ence of 2OHOA, which would inhibit the PI3K/Akt and ERK pathway and the proliferation
machinery. This leads to cell cycle arrest, apoptosis, differentiation and autophagy.
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cated in the downstream signaling to the afferent nerve ﬁbers that
transmits the output signal from taste buds to the central nervous
system (CNS) [84].
It has been shown that several signal transduction systems are
involved in the regulation of cell proliferation, including the PKC sys-
tem, which may play an important role in fast growing cells [85]. A
key enzyme in this system is phospholipase C, a membrane bound
enzyme that produces the secondmessenger DAG for PKC activation.
Phospholipase C is regulated by G proteins, which are in turn sensi-
tive to the presence of omega 6 γ-LNA in the membrane [86].
High olive oil consumption reduces the incidence of cardiovascular
disease and several types of cancer [9]. Olive oil intake increases the
levels of OA,which canmodulate themembrane structure and concom-
itantly, the localization and/or activity of signaling proteins (G-proteins,
PKC and adenylyl cyclase) [87,88]. Regulation of adenylyl cyclase ac-
tivity by G proteins controls blood pressure [89], consistent with the
hypotensive effects of OA derivatives [4,90,91]. 2OHOA, is a potent
anti-cancer drug that induces cell cycle arrest in human lung cancer
cells [92] and apoptosis in human leukemia cells [93]. Its anti-cancer
activity has been associated with different cell effects. On the one
hand, this molecule augments the propensity of membrane lipids
to organize into non-lamellar, HII structures, promoting the subse-
quent recruitment of PKC to the cell membrane after 15–60 min
[92]. This event is followed by activation of p21CIP1, cyclin-cdk inhi-
bition, pRb hypophosphorylation and E2F1 knockdown. E2F1 is a
critical transcription factor that regulates several genes involved in
cell proliferation, including DHFR. The down-regulation of DHFR
impairs DNA synthesis, which results in either cell cycle arrest or apo-
ptosis [94,95]. On the other hand, treatmentwith 2OHOA induces trans-
location of Ras from themembrane to the cytoplasm in the ﬁrst 10 min,
which inhibits theMAP kinase pathway and dampens the activity of the
PI3K/Akt pathway, downregulating cyclin D-cdk4/6 expression and
provoking hypophosphorylation of the retinoblastoma protein [96]
(Fig. 2). 2OHOA also causes a deregulation of phospholipidmetabolism,
which includes a dramatic increase of SM, ceramide, cerebrosides
and lactosyl-ceramide after 6 h in U118 human glioma cells [97]. Be-
sides, the increase in SM content, due to activation of sphingomyelin
synthases, correlates with a decrease of PC and PE cell levels [98].
The gray matter of the frontal lobe and hippocampus in the brain
of AD patients has a lower DHA content than that of healthy individ-
uals [99]. Fish oil enriched in DHA has been shown to reduce Aβ42
production and to have a strong neuroprotective effect on primary
cultures of human neurons [100]. DHA promotes neuronal survival by
facilitating the membrane translocation and activation of Akt through
its capacity to increase phosphatidylserine levels, the main acidic phos-
pholipid in the cell membrane [101]. Indeed, it is known that high
phosphatidylserine content increases hippocampal synaptic efﬁcacy
[102].
5. Natural fatty acids in human health
Fatty acids are part of the fat contained in food products and they
contribute to their ﬂavor and consistency, and lead to the feeling of
fullness when eating. Moreover, fat, and fatty acids in particular,
are a major source of energy and they aid the absorption of lipophilic
substances like vitamins A, D, E and K. Humans lack the ability to synthe-
size omega−3 from omega−6 fatty acids, and vice versa, and they lack
Δ12- and Δ15-desaturase activities, which are responsible for the forma-
tion of a double bond in the carbon 12 and 15 of an acyl chain, respec-
tively. Thus, the omega−3 fatty acid α-LNA (18:3Δc9,12,15) and the
omega−6 fatty acid LA (18:2Δc9,12) are the two essential fatty
acids in humans (i.e., they must be incorporated into the metabolism
through the diet) [103,104]. From these, other fatty acids can be pro-
duced by human cells through different metabolic pathways (Fig. 3).
For instance, through desaturation and chain elongation reactions,LA serves as the precursor for omega−6 γ-LNA (18:2Δc6,9,12) and
ARA (20:4Δc5,8,11,14). On the other hand, omega−3 α-LNA can give
rise to other omega−3 counterparts such as EPA (20:5Δc5,8,11,14,17)
and subsequently, DHA (22:6Δc4,7,10,13,16,19). However, the capacity to
convert LA to ARA and α-LNA to DHA is costly in metabolic terms and
their dietary absorption may be required for the correct development
of brain and retinal tissue in infants [105]. In fact, studies have shown
that breast-fed infants have a greater mean percentage of DHA (by
weight) than formula-fed infants. Moreover, supplementation of ma-
ternal diet during pregnancy and breastfeeding with cod liver oil,
which is enriched in DHA and EPA, improve children's intelligence quo-
tient at 4 years of age compared with corn-oil supplementation [106].
In recent years, much attention has been paid to fatty acids due to
their implications in human health. The amount and type of fatty acids
consumed are directly involved in the etiology of various diseases,
Fig. 3. Metabolism of omega−3 and omega−6 fatty acids. Different omega−3 and
omega−6 fatty acids are produced through elongation and desaturation of the essential
α-LNA and LA fatty acids, respectively. The addition of double bonds and the elongation
of the acyl chains occur in the endoplasmic reticulum, while the ﬁnal step in the synthesis
of the omega−3 DHA and the omega−6 docosopentaenoic acid consists of a single reac-
tion from β-oxidation in the peroxisome.
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tion, cardiovascular disease, psychiatric disorders, immunity and in-
ﬂammatory disease, kidney disease, liver disease and aging [107].
Dietary fatty acids are essential for normal growth, development
and homeostasis, and they fulﬁll a number of important functions.
Increasing evidence indicates that fatty acids and their derived sub-
stances may mediate critical cellular events, including gene activation
and expression, and the regulation of cell signaling [108]. Understand-
ing the mechanisms by which fatty acids exert their biological effects
is important in unraveling the pathogenesis of these disorders, and it
may help provide effective preventivemeasures. For instance, a reduced
risk of coronary heart disease has been described in peoplewho follow a
diet enriched in the omega−3 fatty acids EPA and DHA [109]. Indeed,
the interest in these types of lipids arose from observation that themor-
tality of Greenland Eskimos related to coronary heart disease was only
10% that of Caucasians. Although the amount of body fat in both popu-
lations was similar, the diet of native Eskimos was rich in omega−3
PUFAs. In addition to the lower occurrence of coronary heart disease,
the Eskimo population also had a lower prevalence of inﬂammatory
and immune diseases like asthma, psoriasis or rheumatoid arthritis
[110].
The beneﬁcial effect of these lipids has become so popular that
dietary supplements containing omega−3 fatty acids have become
available as nutraceutics. By contrast, consumption of saturated
and trans unsaturated fatty acids favors the increase of low-densitylipoprotein Cho, which increases the risk of coronary heart disease
[111]. Moreover, many countries have adopted guidelines indicating
the amount of trans fat per serving on the nutritional labels of food
products. Interestingly, few reports have demonstrated deﬁnitive rela-
tionships between dietary trans fatty acids and obesity [112], although
in recent decades, the prevalence of obesity has increased steadily,
mainly in developed countries, and it has been considered as an impor-
tant risk factor contributing to the development of the three leading
causes of death—cardiovascular disease, cancer and diabetes—as well
as other disorders worldwide [113].
It has been proposed that elevated omega−6 fatty acid intake may
promote inﬂammation, while omega−3 fatty acids help reduce it. For
instance, omega−6 ARA is the precursor of the pro-inﬂammatory mol-
ecules prostaglandins, thromboxanes, prostacyclins and leukotrienes
[114]. However, there are several different types of omega−6 fatty
acids and not all promote inﬂammation. In fact, γ-LNA is known to pos-
sess anti-inﬂammatory properties [6]. Indeed, a healthy diet may need
to establish a balance between omega−3 and omega−6 fatty acids to
equilibrate cell activity [115]. It has been estimated that humans have
evolved on a diet based on an omega−6/omega−3 ratio of approxi-
mately 1, whereas this ratio has nowadays increased to 15–20/1, indi-
cating that Western diets are deﬁcient in omega−3 fatty acids [116].
However, differences can also be found between current diets in differ-
ent regions and, interestingly, the omega−6/omega−3 fatty acid plas-
ma ratio is substantially lower in theMediterranean (2.60 ± 0.19) than
in the Swedish diet (4.72 ± 0.19, p b 0.0001) [117].
In 2010, the Mediterranean diet was recognized by the UNESCO
as an Intangible Cultural Heritage of Humanity. This dietary pattern
is characterized by a high consumption of plant foods (i.e. vegeta-
bles, fruits, beans and cereals), a high intake of olive oil, enriched in
cis omega−9 OA (C18:1Δc9), moderate ﬁsh intake, low-to-moderate
intake of dairy products, low meat consumption and the consumption
of wine in moderate amounts during meals. A study carried out over
5 years in 6174 volunteers led to the conclusion that this type of diet,
with a higher monounsaturated-to-saturated fatty acid ratio, is related
to more favorable cognitive capacities in older age [118]. In line with
this, the Mediterranean diet is associated with a blood pressure reduc-
tion and lower incidence of hypertension, which was directly linked
to OA intake [4,119]. It has been proposed that the most abundant
fatty acid in olive oil, OA, is responsible for the decrease of blood
pressure associated with high olive oil consumption. The intake of
olive oil increases OA levels in membranes, which regulates membrane
lipid structure by increasing the propensity to form HII phases in the
lipid bilayers [35]. The subsequent reduction in blood pressure is mod-
ulated by the regulatory effects on G protein-associated signaling cas-
cades (α2A/D-adrenoreceptor/G protein/adenylyl cyclase-cAMP/PKA)
[88]. Interestingly, elaidic (C18:1Δt9) and stearic (C18:0) acids, the re-
spective trans-doubled-bonded and saturated OA analogs, have no hy-
potensive activity, indicating that the molecular mechanisms that link
membrane lipid structure and blood pressure regulation are very spe-
ciﬁc. This is most likely due to the divergent structural effects on the
lipid bilayer (see below). Similarly, soybean oil does not reduce blood
pressure and given its low percentage of OA, this favors the hypothesis
that the hypotensive effect of olive oil is due to OA [4].
OA is also known for its beneﬁcial effects on cancer. Thus, OA can
down-regulate the overexpression of erbB-2, an oncogene involved
in the metastasis of several human cancers and it can also induce ap-
optosis in carcinoma cells, possibly related to an increase of ROS
levels and caspase-3 activity [120]. Protein:OA complexes, such as
the so-called HAMLET (human α-lactalbumin made lethal to tumor
cells) and BAMLET (bovine α-lactalbumin made lethal to tumor cells),
have generated great interest in the antitumoral research ﬁeld [[121]
and references therein]. HAMLET and BAMLET are formed by the bind-
ing of OA to a partially unfolded conformation of human and bovine α-
lactalbumin, respectively, and they have been shown to possess cyto-
toxic effects both in vitro [122] and in vivo [123]. This cytotoxic effect
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urated fatty acids, and it diminishes when they were coupled to the
saturated SA. The mechanisms of action of these complexes seem
to be related to apoptotic processes like caspase activation, loss of
mitochondrial potential and chromatin destabilization. HAMLET
was also observed to bind to and inducemembrane permeabilization
in artiﬁcial model membranes and living cells [124], which may be
consistent with the previously described effects.
Natural lipid molecules derived from free fatty acids are also
known for their inﬂuence on cell function. Thus, resolvins and
protectins are natural hydroxylated derivatives of omega−3 EPA
and DHA that are known to possess anti-inﬂammatory activity [125].
DHA is hydroxylated at carbon 17 by the enzyme 15-lipoxygenase and
by acetylated COX-2, producing 17S- and 17R-hydroxydocosahexaenoic
acid (17OHDHA), respectively. These compounds are further
hydroxylated to give rise to the trihydroxy derivatives 17-(S/R)-
resolvins D1, D2, D3 and D4, and the dihydroxy compound 17-(S/R)-
protectin (Fig. 4A). On the other hand, EPA is hydroxylated to 18-(S/R)-
hydroxyeicosapentaenoic acid (18OHEPA), which is further processed
to form 18-(S/R)-resolvins E1 and E2 (Fig. 4B). Given the importance of
17HDHA and 18OHEPA as indicators of the presence of resolvins and
protectins, it is important to note that these metabolites can be found in
human and mice blood [126] and that their presence is directly related
to the intake of omega−3 in transgenic fat-1 mice [127].
Protectin D1 offers protection against AD by regulating secretase-
mediated production of the Aβ peptide, by downregulating pro-
inﬂammatory gene expression and by promoting cell survival. In
human neural cells overexpressing beta-amyloid precursor protein,
the lipid mediator suppressed Aβ42 shedding by downregulating
β-secretase while activating α-secretase, thereby shifting amyloidFig. 4. Resolvin and protectin synthetic pathways. (A) Formation of the D-series of resolvins
and protectins commences with the hydroxylation of DHA (D nomenclature derives from
DHA) that gives rise to the S- andR-isomers of 17-hydroxydocosahexaenoic acid. Subsequent
hydroxylation reactions produce the different isomers of resolvinsD1-4 andprotectinD1. (B)
EPA is theprecursor of the E-series of resolvins (namederived fromEPA) that beginswith the
production of the 18S- and 18R-hydroxyeicosapentaenoic acid.
Adapted from [125].precursor protein cleavage from the cytotoxic amyloidogenic path-
way towards the non-amyloidogenic, neurotrophic pathway [128].
Inﬂammation may have beneﬁcial effect for host defense, al-
though a resolution of inﬂammation is necessary in order to avoid
chronic inﬂammatory situations. The term resolvins or ‘resolution-
phase interaction products’ was coined by Serhan and colleagues,
because these compounds were ﬁrst encountered in resolving in-
ﬂammatory exudates of murine models [129]. These compounds
were shown to offer protection from acute ischemic kidney injury
[130] and they alleviate induced colitis by reducing the levels of pro-
inﬂammatory cytokines [131]. They are also effective against asthma,
since they regulate the migration and recruitment of immune cells
and they decrease the levels of pro-inﬂammatory interleukins [132].
Another DHA-derived monohydroxy lipid that is produced by 5-
lipoxygenase and that possesses potent biological activity is 4-
hydroxydocosahexaenoic acid. This molecule directly inhibits
endothelial cell proliferation and angiogenesis via peroxisome
proliferator-activated receptor γ (PPARγ), a mechanism that is inde-
pendent of its anti-inﬂammatory effects [133]. However, not all
hydroxylated lipid derivatives are beneﬁcial for human health. Indeed,
trans-4-hydroxy-2-hexenal is an aldehyde side product of DHA peroxi-
dation that is accumulated in the CNS of patients with AD and it is
thought to induce neurotoxicity [134].
Another interesting group of fatty acids is that formed by the
conjugated linoleic acid. This is a family of 28 naturally occurring
isomers of LA, with both trans and cis double bonds produced by
bio-hydrogenation in ruminants or by bacteria from the gastro-
intestinal tract of humans. The consumption of ruminant meat
(beef and lamb) and dairy products (milk and cheese) is the main
source of dietary conjugated linoleic acids. In this case, the predom-
inant isomer formed is 9-cis, 11-trans, also known as rumenic acid,
and unlike other trans double bond-containing fatty acids, it may
have beneﬁcial effects on human health [135]. However, other con-
jugated linoleic acids are also available, mostly a mixture of 9-cis,
11-trans, 10-trans, and 12-cis isomers. These fatty acids have been
shown to produce effects against cancer and inﬂammation, as well
as changes in cell metabolism that lead to weight loss, although
their true effect and the mechanism of action in such processes re-
main unclear [136,137]. Interestingly, conjugated linolenic acids,
which are more abundant than conjugated linoleic acids in natural
sources, have also been recently described as inhibitors of colorectal
tumorigenesis [138].
Finally, naturally occurring omega−9 fatty acid derivatives also
exist. Oleamide is an amide derivative of the OA that can be found
endogenously in cerebrospinal ﬂuid when animals are sleep de-
prived. This compound induces sleep in rats when injected at doses
above 5 mg [139] and its mechanism of action seems to be related
to the modulation of receptors that activate G proteins, playing a
role in alertness and sleep [140]. Oleamide is structurally related to
endogenous cannabinoids and it has the ability to bind to the canna-
binoid receptor, as well as possessing signiﬁcant hypnotic, analgesic
and anxiolytic effects but only producing very weak dependence
[141].
The regulation of membrane structure, at least partially, explains
the modulation exerted by some natural fatty acids on membrane
and cell function. Indeed, the unsaturated fatty acids OA, LA and
LNA stabilize HII structures in PE membranes, and OA increases ﬂuid-
ity in the lamellar phase [35], although neither EA nor SA alter the
phospholipid mesomorphism. Interestingly, membrane-modifying
natural fatty acids are effective in certain therapeutic applications.
For instance, blood pressure is decreased in rats upon treatment
with OA but not with EA or SA [4]. Similarly, OA but not EA induces
weight loss in rats [142]. Concerning their antitumoral properties,
cis-unsaturated OA has a moderate antiproliferative effect on
tumor cells [93], while its trans-unsaturated congener EA does not
inhibit cell growth at all.
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The seven-carbon heptanoic acid and the corresponding triacylglyc-
eride triheptanoin have proven useful to treat glycogen metabolic
syndrome. These seven-carbon acyl chain moieties are metabolized
by β-oxidation to produce propionyl-CoA, which is subsequently
carboxylated to succinyl-CoA. The latter is one of the metabolites of
the Krebs cycle and its incorporation in the metabolic pathway
results in anaplerosis (reﬁlling of the tricarboxylic acid cycle).
Heptanoate is also transformed in the liver to the C5 ketones, β-
ketopentanoate and/or β-hydroxypentanoate, which are thought to
cross the blood–brain barrier and enter the brain [143]. This compound
has been shown to be effective in certain therapeutic processes, such as
in glycogen metabolic syndrome IV, also known as Adult Polyglucosan
Body Disease (APBD). APBD is a rare progressive neurodegenerative
disorder, most often affecting adults of Ashkenazi Jewish origin and
characterized by neurogenic bladder, progressive difﬁculty with
walking and sensory abnormalities in the lower extremities typically
developed in the 4th or 5th decade of life. The pathogenesis of the
disease includes the deposition of intracellular polyglucosan bodies
(amylopectin-like polysaccharides) in the peripheral and CNS cells,
which is often associated with a partial deﬁciency of glycogen
branching enzyme, a protein that catalyzes the α(1 → 6)glycosidic
bond during the synthesis of glycogen. It is hypothesized that de-
creased glycogen degradation leads to an energy deﬁcit in cells of
the nervous system. Therefore, anaplerotic therapy may supply the
substrates required for the citric acid cycle in order to correct the energy
deﬁciency. In fact, a study has been performed with APBD patients
consisting in dietary supplementation with the synthetic triglyceride
triheptanoin, concluding that patients with APBD experienced a stabili-
zation of disease progression and in most cases, limited functional
recovery [144]. Besides APBD, oral triheptanoin has recently been dis-
covered to be effective as anticonvulsant in acute and chronic mouse
seizure models, representing a potential treatment for epilepsy [145].
Bacterial lipids have also been studied for their potential therapeutic
use. Thus, ONO-4007 is a synthetic lipid A derivative with antitumoral
effects and with low endotoxic activities [146]. Lipid A is a lipid compo-
nent of an endotoxin responsible for toxicity in Gram-negative bacteria,
which consists of two glucosamine units with attached acyl chains, and
normally one phosphate group on each carbohydrate. Its synthetic
derivative, ONO-4007 was effective against KDH-8, a tumor necrosis
factor (TNF)-sensitive rat hepatoma cell line, although interestingly
it showed no antitumor activity in any TNF-resistant cell line. These
results suggest thatONO-4007maybe therapeutically useful for the treat-
ment of TNFα-sensitive tumors and its mechanism of action seems to be
related to enhanced production of TNFα in tumor tissues [7].
The beneﬁcial effects of OA for human health and that of other fatty
acids has been proven, however, their efﬁciency is limited due to their
metabolic use through β-oxidation in the mitochondria. However, the
2-hydroxylated OA analog (2OHOA) is not degraded by β-oxidation
but by the α-oxidation pathway [142]. The 2-hydroxy-phytanoyl-CoA
lyase is the rate-limiting enzyme of theα-pathway [147] and it may be-
come rapidly saturated at low substrate concentrations, as it represents
a secondary oxidation pathway for non-abundant natural fatty acids. As
a consequence, 2OHOA's half-life is longer than its naturally occurring
analog OA and therefore, its therapeutic effects last longer. The marked
enhancement of the antiproliferative activity of 2OHOA with respect to
OA in human cancer cells, in the absence of any apparent toxic effects, is
evidence of the improved therapeutic efﬁciency of this hydroxylated
fatty acid. Indeed, exposure to 2OHOA inhibits the growth of cancer
cells and tumor growth in animal models [96].
Interestingly, naturally occurring 2-hydroxylated fatty acids exist.
For instance, C22 to C26 saturated and monounsaturated 2-hydroxy
fatty acids have been found as major lipid components of the cell wall
in three marine chlorophytes [148], and detritus from the sea-grassZostera muelleri is a source of 2-hydroxy acids (0.6 μg/g) that range
from C18 to C28, including different mono- and polyunsaturated de-
rivatives [149]. Seed oils from Thymus vulgaris are enriched in 2-
hydroxylinolenic acid (13%) [150], while the seed oil of Salvia nilotica
contains 0.6% 2-hydroxyoleic, 4.2% 2-hydroxylinoleic and 5.4% 2-
hydroxylinolenic acids [151]. Moreover, hydroxylated DHA deriva-
tives may also be found among the aforementioned resolvins [125].
During the last few years, a number of 2-hydroxylated fatty acid de-
rivatives other than 2OHOA have been rationally designed for the
treatment of cancer, inﬂammation, AD, obesity, diabetes, spinal cord in-
jury, etc.… Indeed, the data available indicate that themechanism of ac-
tion of these compounds is related to their capacity to modulate the
lipid structure of the membrane [36,88,152]. In this context, 2OHOA
has proved effective in reducing blood pressure in hypertensive rats
through a mechanism that involves the modulation of membrane
lipid composition, and of the membrane biophysical properties [153].
Also, 2OHOA is currently being studied in phase I/IIa clinical trials
for the treatment of solid tumors (code NCT01792310) [154] and it
is under preclinical development for the treatment of spinal cord
injury. 2OHARA has been described as a new non-steroidal anti-
inﬂammatory drug that can inhibit COX1 and COX2 activity, thereby
reducing the synthesis of pro-inﬂammatory mediators. Molecular
dynamics have predicted binding competition between 2OHARA
and the proinﬂammatory fatty acid ARA to COX1 and COX2. Moreover,
in addition to the in vitro inhibition of COX1 and COX2 activity, 2OHARA
decreased plasma TNFα levels in vivo [155]. Finally, 2OHDHAhas arisen
as an interesting candidate to revert the cognitive deﬁciencies asso-
ciated with neurodegeneration, such as in AD. This fatty acid deriva-
tive decreases Aβ accumulation in parallel with a recovery of
cognitive scores in animal models. These results are consistent with
the reduced binding of oligomeric and ﬁbrillar Aβ lipid raft-like ves-
icles in the presence of 2OHDHA [156,157]. All these 2-hydroxylated
compounds are thought to act by regulating signal transduction
through Membrane Lipid Therapy, an approach that aims to regulate
membrane lipid organization through structure–function principles
[158]. Changes in the membrane's physico-chemical properties,
such as the lateral pressure, membrane ﬂuidity or phase behavior
may regulate the localization and activity of relevant signaling pro-
teins, resulting in the regulation of gene expression and a reversion
of pathological states within cells.
7. Concluding remarks
Fatty acids are no longer considered as mere energy sources or
constituents of complex lipids but rather, it is now clear that they
may also exert important changes in cell membranes leading to
modulation of cell functions. Both natural and synthetic fatty acids
have been proven to modify biophysical parameters of membranes,
such as their ﬂuidity, permeability and domain formation, as well
as cell processes involving cell fusion/ﬁssion (endo/exocytosis, cell
division), signal transduction, membrane protein activities, and anti-
proliferative control. Thus, understanding how all these processes
occur and considering the biophysical properties of lipid membranes
as a drug target have led to the design of new therapeutic approaches
that are proving to be effective against cell dysfunction, such as those
events responsible for cancer, neurodegeneration or metabolic
diseases.Abbreviations
2OHARA 2-hydroxyarachidonic acid
2OHDHA 2-hydroxydocosahexaenoic acid
2OHOA 2-hydroxyoleic acid
α-LNA alpha linolenic acid
γ-LNA gamma linolenic acid
Aβ amyloid-β
ARA arachidonic acid
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CNS central nervous system
DEPE 1,2-dielaidoyl-sn-glycero-3-phosphoethanolamine
DHA docosahexaenoic acid
DHFR dihydrofolate reductase
DMPC 1,2-dimiristoyl-sn-3-phosphocholine
DOPE 1,2-dioleyl-sn-glycero-3-phosphoethanolamine
DPH 1,6-diphenyl-1,3,5-hexatriene
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
DSC differential scanning calorimetry
EA elaidic acid
EPA eicosapentaenoic acid
FFA free fatty acid
LA linoleic acid
Lα liquid crystalline or ﬂuid phase
Lβ gel phase
Ld liquid-disordered
Lo liquid-ordered
MUFA monounsaturated fatty acid
OA oleic acid
PC phosphatidylcholine
PE phosphatidylethanolamine
POPE 1-palmitoyl-2-oleoyl-sn-glycero-phosphoethanolamine
PPARγ peroxisome proliferator activated receptor γ
PUFA polyunsaturated fatty acid
SA stearic acid
SM sphingomyelin
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